Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative Outcomes.

What Was Tested

The paper reports a study of Glucagon, published as an observational study.

To assess rates of surgical complications and postoperative readmission in diabetic patients with and without active perioperative prescriptions for glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.

Why It Was Studied

With the rapid growth of GLP-1 RA use in the United States, it is important to understand the potential effect of these drugs on surgical outcomes broadly.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

In this retrospective, observational cohort analysis, patients with a diagnosis of type 1 or type 2 diabetes undergoing a surgical procedure at a multicenter quaternary-care health care system between February 2020 and July 2023 were included.

Propensity score matching was performed between procedures in patients with and without an active GLP-1 RA prescription.

How the Study Was Run

The design is described as multicenter.

Running at several centres spread the Glucagon study over different clinics and patient groups.

What Was Measured

With the rapid growth of GLP-1 RA use in the United States, it is important to understand the potential effect of these drugs on surgical outcomes broadly.

Topics PubMed links to this paper include Postoperative Complications, Glucagon-Like Peptide-1 Receptor Agonists, Patient Readmission, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Propensity Score and Diabetes Mellitus, Type 1.

What This Means in Plain Language

The paper is a multicenter study of Glucagon.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Annals of surgery), a journal based in United States.

More context: the Glucagon compound page, all human trials.